Study S001307

A Study on the Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes Combined With Metabolic-associated Fatty Liver Disease and Its Molecular Mechanisms

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07272343
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: RECRUITING
Enrollment: 100
Start: 2023-02-10
Primary completion: 2026-06-30
Lead sponsor: Second Affiliated Hospital of Nanchang University
Conditions: Type 2 Diabetes Mellitus (T2DM); Semaglutide; Caloric Restriction
Interventions: DRUG:semaglutide; BEHAVIORAL:caloric restriction
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

HbA1c [From enrollment to the end of treatment at 12 weeks]
FPG [From enrollment to the end of treatment at 12 weeks]
2hPG [From enrollment to the end of treatment at 12 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.